| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501819 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(2 years from now) | |
| US9382191 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(2 years from now) | |
| US8450375 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(2 years from now) | |
| US8501818 | HELSINN | Stabilized compositions of alkylating agents and methods of using same |
Mar, 2026
(2 years from now) | |
| US7838564 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(2 years from now) | |
| US7872050 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Jul, 2029
(5 years from now) | |
Valchlor is owned by Helsinn.
Valchlor contains Mechlorethamine Hydrochloride.
Valchlor has a total of 6 drug patents out of which 0 drug patents have expired.
Valchlor was authorised for market use on 23 August, 2013.
Valchlor is available in gel;topical dosage forms.
Valchlor can be used as alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy.
The generics of Valchlor are possible to be released after 08 July, 2029.
Drugs and Companies using MECHLORETHAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy
Dosage: GEL;TOPICAL
VALCHLOR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic